Surface protein analysis of a non-syncytium inducing HIV-1 isolate.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Surface protein analysis of a non-syncytium inducing HIV-1 isolate.

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:72 (abstract no. SB3). Unique Identifier : AIDSLINE ASHM5/94349032
Fryer KM; Deacon NJ; Land SA; McPhee DA; Macfarlane Burnet Centre for Medical Research, Fairfield, Vic.

Abstract: An Australian HIV-1 isolate that is non-syncytium inducing (NSI), and has reduced cytopathic effect on peripheral blood mononuclear cells (PBMCs) has been characterised. The biochemical properties and DNA sequence of this isolate (243925) were compared with a typical syncytium inducing (SI) isolate 228200. Both isolates replicate well in PBMCs and are neutralised by similar concentrations of sCD4 and OKT4a, but the NSI isolate does not down-modulate CD4 from the surface of infected cells. Phylogeny analysis based on envelope protein DNA sequence has mapped both to clade B, with North American isolates. The nucleotide sequences of the V3 loop of envelope of the two viruses correlate with published syncytium and non-syncytium inducing virus sequences (Fouchier et al., 1992). Western blot analysis has demonstrated greater heterogeneity in the envelope protein on the surface of cells infected with 243925 compared with infection by the NSI isolate. The surface glycoprotein gp 120 was detected on the viral particles of the NSI isolate only, suggesting that the protein is shed from the surface of the SI isolate. These studies confirm the similarity of Australian HIV-1 isolates to American isolates, and suggest a role for the stability of the envelope protein in HIV-1 syncytium formation.

Keywords: Australia Cell Line Cytopathogenic Effect, Viral/GENETICS CD4-Positive T-Lymphocytes/MICROBIOLOGY DNA, Viral/*GENETICS Gene Expression Regulation, Viral/PHYSIOLOGY Giant Cells/*MICROBIOLOGY Human HIV Envelope Protein gp120/GENETICS HIV-1/*GENETICS Monocytes/*MICROBIOLOGY ABSTRACT
941230
M94C4195

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .